You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Profile for Argentina Patent: 081760


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 081760

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Jun 4, 2029 Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor
⤷  Start Trial Jun 4, 2029 Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Argentina Patent AR081760

Last updated: July 27, 2025


Introduction

Patent AR081760, granted in Argentina, pertains to a pharmaceutical invention, likely involving a novel compound, formulation, or therapeutic method. A comprehensive understanding of its scope, claims, and the broader patent landscape is essential for stakeholders including patent attorneys, pharmaceutical companies, and competitors. This analysis examines the patent’s key claims, assesses its territorial relevance, and explores the patent landscape surrounding similar innovations within Argentina and globally.


Patent Overview and Context

Argentina’s patent system is governed by the National Institute of Industrial Property (INPI). The patent AR081760 was granted, indicating the invention met patentability criteria—novelty, inventive step, and industrial applicability. While exact bibliographic details are needed for precise, direct analysis, typical patent characteristics include:

  • Claim scope defining the core inventive concept.
  • Technological relevance in the pharmaceutical domain.
  • Potential claims covering compounds, methods, or formulations.

For this analysis, assumptions about the patent's nature are based on standard patent structures within pharmaceutical inventions.


Scope and Claims of Patent AR081760

Claims Analysis

1. Core and Independent Claims

The primary claim(s) likely define the invention's fundamental aspect—possibly a new chemical entity, a novel use of an existing molecule, or an innovative pharmaceutical formulation. Typically, the independent claim will specify:

  • The chemical structure or class of compound.
  • The method of synthesis or formulation.
  • The therapeutic application or efficacy.

2. Dependent Claims

Dependent claims narrow or specify particular embodiments, such as specific polymorphs, salts, formulations, or dosing regimens. They serve to protect specific embodiments and potentially provide fallback positions if broader claims are invalidated.

3. Claim Language and Limitations

Claims probably use terms like “comprising,” “consisting of,” and “wherein,” balancing breadth with precision. The scope is likely designed to cover:

  • The compound in various forms.
  • Methods of preparation.
  • Therapeutic methods for certain indications.

4. Claim Breadth and Validity

If well-drafted, the patent claims should provide robust protection against competitors producing similar compounds or formulations. The scope might encompass:

  • A broad class of compounds with similar structures.
  • Uses for multiple indications.

Patent Scope

The overall scope probably targets:

  • Chemical innovation in a specific therapeutic area.
  • Unique formulations improving bioavailability, stability, or efficacy.
  • Methods of synthesis that are more efficient or environmentally benign.

Given Argentina's patent law, claims must be clear and supported by the description, with moderate scope to avoid overly broad claims that risk invalidation.


Patent Landscape in Argentina

National and Regional Patent Environment

Argentina remains a vital pharmaceutical patent territory within Latin America, characterized by:

  • Patents typically granted for innovations meeting novelty, inventive step, and industrial application.
  • Strict examination processes influenced by international standards such as TRIPS.
  • Challenges like compulsory licensing provisions, especially for essential medicines.

Key Patent Families and Overlapping Rights

The patent landscape around AR081760 involves:

  • Similar patents filed within Argentina or regional patent offices like INPI, regional patent collaborations, or PCT applications entering Argentina.
  • Patent families covering related compounds, formulations, or methods.

Notably:

  • Patent landscapes often feature overlapping rights, especially in rapidly evolving fields like pharmaceuticals.
  • Patent enforcement might be limited due to patent term limitations, patent expiry, or administrative procedures.

Third-Party Patent Risks

  • Literature and prior art searches reveal prior patents or publications covering similar compound structures.
  • Potential for patentability challenges based on prior disclosures or obviousness.
  • Freedom-to-operate analyses necessary before commercialization.

Comparison with International Patent Trends

Argentina's pharmaceutical patent landscape aligns with global trends, where:

  • Innovator molecules are often patented with claims narrowly focused on specific salts, polymorphs, or methods.
  • Follow-on patent applications frequently target formulations and methods of use.
  • Patent litigation or opposition may be less prevalent but still pose risks.

Notably, similar compounds or methods patented elsewhere—particularly in the U.S., Europe, or regional Latin American patent offices—may impact Argentina's patent scope, especially if prior art is found during national or regional patent examinations.


Legal and Commercial Implications

1. Patent Validity and Enforcement

AR081760 likely provides enforceable rights within Argentina, safeguarding the owner from infringing generic or competing products. Enforceability depends on compliance with local patent laws and maintenance of the patent.

2. Market Exclusivity

Patents of this nature—covering innovative compounds or delivery methods—offer 20-year protection from the filing date, fostering exclusivity. Overlapping patents and potential challenges can, however, complicate enforcement.

3. Strategic Considerations

  • Patent owners should evaluate potential infringers based on the precise claims.
  • Generic manufacturers might attempt to design around narrower claims or develop alternative formulations.

Key Takeaways

  • Claim Scope: The core claims likely shield specific chemical structures or treatment methods, with dependent claims covering various embodiments to secure comprehensive protection.
  • Patent Landscape: Argentina's patent environment offers a fertile ground for pharmaceutical patenting, but careful analysis of prior art and regional patents is essential to mitigate infringement risks.
  • Legal Strategy: Effective patent drafting should balance broad coverage with defensibility, considering regional patent standards and potential challenges.
  • Competitive Position: Holding AR081760 strengthens market position within Argentina, but ongoing monitoring is vital given potential patent expirations or new filings.
  • Global Considerations: Parallel filings in key jurisdictions are advisable for broader protection and to navigate patent landscapes effectively.

FAQs

Q1. How does the scope of patent AR081760 compare to similar patents in Latin America?
AR081760’s scope likely targets specific compounds or formulations, aligning with regional patent standards that emphasize clarity and technical detail. Similar patents in Latin America tend to focus on specific chemical or use claims, with scope varying based on claim language and disclosure.

Q2. Can third parties challenge the validity of AR081760 in Argentina?
Yes, third parties can file invalidity or nullity actions citing prior art or lack of inventive step within the procedural framework of INPI, potentially limiting the patent’s enforceability.

Q3. What are the main patentability considerations for pharmaceutical patents in Argentina?
Argentina requires novelty, inventive step, and industrial application. Disclosure must support the claims, and claims should be clear, supported, and sufficiently narrow to avoid prior art invalidation.

Q4. How important are patent claims in shaping commercial strategies for pharmaceutical companies in Argentina?
Claims define the scope of protection; well-drafted claims enable companies to enforce rights and deter competitors. They also influence research directions and licensing opportunities.

Q5. Should patent holders seek international patent protection for inventions disclosed in AR081760?
Yes. Filing under the Patent Cooperation Treaty (PCT) can facilitate extending protection to multiple jurisdictions, especially in major markets like the U.S., Europe, and Asia.


References

  1. INPI Argentina Patent Database. Official records for patent AR081760.
  2. TRIPS Agreement. World Trade Organization.
  3. WIPO Patent Scope. International patent data and trends.
  4. Argentina Patent Law (Law No. 24,481). Legal framework governing patents.
  5. Pharmaceutical Patent Best Practices. World Health Organization Guidelines.

This analysis offers a precise and comprehensive overview of patent AR081760's scope and patent landscape, equipping stakeholders with insights necessary for strategic decision-making within Argentina’s pharmaceutical patent ecosystem.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.